A strategy for developing new treatment paradigms for neuropsychiatric and neurocognitive symptoms in Alzheimer's disease

Frontiers in Pharmacology

Volumn 4 APR, Issue , 2013, Pages

  Geerts, Hugo ^a,b   Roberts, Patrick ^a,c   Spiros, Athan ^a   Carr, Robert ^a  

^a In Silico Biosciences   (United States)

^b UNIVERSITY OF PENNSYLVANIA   (United States)

^c OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

Author keywords

Alzheimer's disease; Apathy; Cognitive disorders; Computer simulation; Drug discovery

Indexed keywords

6 QUINOXALINECARBOXYLIC ACID PIPERIDIDE; ATORVASTATIN; AVAGACESTAT; BAPINEUZUMAB; CEVIMELINE; DIMEBON; EPTASTIGMINE; HOMOTAURINE; HUPERZINE B; IBUPROFEN; IDEBENONE; ISPRONICLINE; LETEPRINIM; LEUPRORELIN; LINOPIRDINE; METRIFONATE; NAPROXEN; PF 4494700; PHENSERINE; PHYSOSTIGMINE; PONEZUMAB; ROFECOXIB; ROSIGLITAZONE; SABELUZOLE; SEMAGACESTAT; SIMVASTATIN; SOLANEZUMAB; TARENFLURBIL; TESOFENSINE; UNINDEXED DRUG; AMYLOID PROTEIN; ARIPIPRAZOLE; BIFEPRUNOX; GAMMA SECRETASE INHIBITOR; INOSITOL; METHYLPHENIDATE; NEUROTRANSMITTER; SCYLLO INOSITOL; SEMAGECESTAT; TAU PROTEIN; UNCLASSIFIED DRUG;

AGGRESSION; AGITATION; ALZHEIMER DISEASE; APATHY; ARTICLE; CALIBRATION; COGNITION; COGNITIVE DEFECT; COMPUTER SIMULATION; CORPUS STRIATUM; DEMENTIA; DEPRESSION; DRUG SCREENING; DRUG TREATMENT FAILURE; HISTOPATHOLOGY; HUMAN; LOCOMOTION; MAZE TEST; MENTAL DISEASE; NEUROPROTECTION; NEUROTRANSMISSION; NONHUMAN; PHENOTYPE; QUANTITATIVE ANALYSIS; QUANTITATIVE SYSTEMS PHARMACOLOGY; SYMPTOMATOLOGY; THALAMUS; WORKING MEMORY; ANALYTIC METHOD; ANATOMICAL VARIATION; DORSAL RAPHE NUCLEUS; DRUG EFFICACY; DRUG PROGRAM; DRUG RESEARCH; ELECTROENCEPHALOGRAM; GENETICS; INTERNEURON; LOCUS CERULEUS; NERVE CELL NETWORK; NEUROPSYCHIATRY; PATHOLOGY; QUALITY OF LIFE; SCHIZOPHRENIA;

EID: 84881511797     PISSN: None     EISSN: 16639812     Source Type: Journal    
DOI: 10.3389/fphar.2013.00047     Document Type: Article

References (82)

1. Akhondzadeh, S., Mohammadi, N., Noroozian, M., Karamghadiri, N., Ghoreishi, A., Jamshidi, A. H., et al. (2009). Added ondansetron for stable schizophrenia: a double blind, placebo controlled trial. Schizophr. Res. 107, 206-212.
2. Ball, M. J. (1977). Neuronal loss, neurofibrillary tangles and granulovacuolar degeneration in the hippocampus with ageing and dementia. A quantitative study. Acta Neuropathol. 37, 111-118.
3. Bartko, S. J., Vendrell, I., Saksida, L. M., and Bussey, T. J. (2011). A computer-automated touchscreen paired-associates learning (PAL) task for mice: impairments following administration of scopolamine or dicyclomine and improvements following donepezil. Psychopharmacology (Berl.) 214, 537-548.
4. Bazhenov, M., Timofeev, I., Steriade, M., and Sejnowski, T. J. (1998). Computational models of thalamocortical augmenting responses. J. Neurosci. 18, 6444-6465.
5. Beaulieu, C. (1993). Numerical data on neocortical neurons in adult rat, with special reference to the GABA population. Brain Res. 609, 284-292.
6. Beaulieu, C., Kisvarday, Z., Somogyi, P., Cynader, M., and Cowey, A. (1992). Quantitative distribution of GABA-immunopositive and -immunonegative neurons and synapses in the monkey striate cortex (area 17). Cereb. Cortex 2, 295-309.
7. Bezprozvanny, I. (2010). The rise and fall of Dimebon. Drug News Perspect. 23, 518-523.
8. Boileau, I., Dagher, A., Leyton, M., Welfeld, K., Booij, L., Diksic, M., et al. (2007). Conditioned dopamine release in humans: a positron emission tomography [11C]raclopride study with amphetamine. J. Neurosci. 27, 3998-4003.
9. Brunner, D., Nestler, E., and Leahy, E. (2002). In need of high-throughput behavioral systems. Drug Discov. Today 7(Suppl.), S107-S112.
10. Carrillo, M. C., Bain, L. J., Frisoni, G. B., and Weiner, M. W. (2012). Worldwide Alzheimer's disease neuroimaging initiative. Alzheimers Dement. 8, 337-342.
11. Castellani, R. J., and Perry, G. (2012). Pathogenesis and disease-modifying therapy in Alzheimer's disease: the flat line of progress. Arch. Med. Res. 43, 694-698.
12. Cuadrado-Tejedor, M., Ricobaraza, A., Frechilla, D., Franco, R., Pérez-Mediavilla, A., and Garcia-Osta, A. (2012). Chronic mild stress accelerates the onset and progression of the Alzheimer's disease phenotype in Tg2576 mice. J. Alzheimers Dis. 28, 567-578.
13. Davies, P., and Maloney, A. J. (1976). Selective loss of central cholinergic neurons in Alzheimer's disease. Lancet 2, 1403.
14. De Deyn, P. P., and Wirshing W. C. (2001). Scales to assess efficacy and safety of pharmacologic agents in the treatment of behavioral and psychological symptoms of dementia. J. Clin. Psychiatry 62(Suppl. 21), 19-22.
15. DeFelipe, J. (2002). Cortical interneurons: from Cajal to 2001. Prog. Brain Res. 136, 215-238.
16. Destexhe, A., Rudolph, M., Fellous, J. M., and Sejnowski, T. J. (2001). Fluctuating synaptic conductances recreate in vivo-like activity in neocortical neurons. Neuroscience 107, 13-24.
17. Durstewitz, D., Seamans, J. K., and Sejnowski, T. J. (2000). Dopamine-mediated stabilization of delay-period activity in a network model of prefrontal cortex. J. Neurophysiol. 83, 1733-1750.
18. Eckert, G. P., Renner, K., Eckert, S. H., Eckmann, J., Hagl, S., Abdel-Kader, R. M., et al. (2012). Mitochondrial dysfunction - a pharmacological target in Alzheimer's disease. Mol. Neurobiol. 46, 136-150.
19. Gauthier, S., Aisen, P. S., Ferris, S. H., Saumier, D., Duong, A., Haine, D., et al. (2009). Effect of tramiprosate in patients with mild-to-moderate Alzheimer's disease: exploratory analyses of the MRI sub-group of the Alphase study. J. Nutr. Health Aging 13, 550-557.
20. Geerts, H. (2009). Of mice and men: bridging the translational disconnect in CNS drug discovery. CNS Drugs 23, 915-926.
21. Geerts, H., Roberts, P., and Spiros, A. (2012). Failure analysis of Dimebon using mechanistic disease modeling: lessons for clinical development of new AD therapies. Alzheimer Dement. 8(Suppl. 311).
22. Geerts, H. (2012). Available at: http://www.alzdiscovery.org/wp-content/uploads/2012/12/december-update-new-research-resources-available.pdf (ADDF website).
23. Geerts, H., Spiros, A., Roberts, P., Twyman, R., Alphs, L., and Grace, A. A. (2012). Blinded prospective evaluation of computer-based mechanistic schizophrenia disease model for predicting drug response. PLoS ONE 7:e49732. doi: 10.1371/journal.pone.0049732
24. Geerts, H., Spiros, A., and Roberts, P. (2013). Negative symptoms in schizophrenia. A quantitative computer-based systems pharmacology approach. ICOSR Meeting 2013, Orlando.
25. Green, R. C., Schneider, L. S., Amato, D. A., Beelen, A. P., Wilcock, G., and Swabb, E. A. (2009). Effect of tarenflurbil on cognitive decline and activities of daily living in patients with mild Alzheimer disease: a randomized controlled trial. JAMA 302, 2557-2564.
26. Grinberg, L. T., Rub, U., Ferretti, R. E., Nitrini, R., Farfel, J. M., Polichiso, L., et al. (2009). The dorsal raphe nucleus shows phospho-tau neurofibrillary changes before the transentorhinal region in Alzheimer's disease. A precocious onset? Neuropathol. Appl. Neurobiol. 35, 406-416.
27. Gruber, A. J., Solla, S. A., Surmeier, D. J., and Houk, J. C. (2003). Modulation of striatal single units by expected reward: a spiny neuron model displaying dopamine-induced bistability. J. Neurophysiol. 90, 1095-1114.
28. Harvey, P. O., Armony, J., Malla, A., and Lepage, M. (2010). Functional neural substrates of self-reported physical anhedonia in non-clinical individuals and in patients with schizophrenia. J. Psychiatr. Res. 44, 707-716.
29. Hashimoto, T., Nguyen, Q. L., Rotaru, D., Keenan, T., Arion, D., Beneyto, M., et al. (2009). Protracted developmental trajectories of GABAA receptor alpha1 and alpha2 subunit expression in primate prefrontal cortex. Biol. Psychiatry 65, 1015-1023.
30. Hendry, S. H., Schwark, H. D., Jones, E. G., and Yan, J. (1987). Numbers and proportions of GABA-immunoreactive neurons in different areas of monkey cerebral cortex. J. Neurosci. 7, 1503-1519.
31. Hewlett, W. A., Fridman, S., Trivedi, B. L., Schmidt, D. E., de Paulis, T., and Ebert, M. H. (1998). Characterization of desamino-5-[125I]iodo-3-methoxy-zacopride ([125I]MIZAC) binding to 5-HT3 receptors in the rat brain. Prog. Neuropsychopharmacol. Biol. Psychiatry 22, 397-410.
32. Holtzman, D., Mandelkow, M. E., and Selkoe, D. J. (2012). Alzheimer disease in 2020. Cold Spring Harb. Perspect. Med. 2, pii: a011585.
33. Ito, K., Ahadieh, S., Corrigan, B., French, J., Fullerton, T., Tensfeldt, T., et al. (2010). Disease progression meta-analysis model in Alzheimer's disease. Alzheimers Dement. 6, 39-53.
34. Jeong, Y. H., Park, C. H., Yoo, J., Shin, K. Y., Ahn, S. M., Kim, H. S., et al. (2006). Chronic stress accelerates learning and memory impairments and increases amyloid deposition in APPV717I-CT100 transgenic mice, an Alzheimer's disease model. FASEB J. 20, 729-731.
35. Juckel, G., Schlagenhauf, F., Koslowski, M., Wüstenberg, T., Villringer, A., Knutson, B., et al. (2006). Dysfunction of ventral striatal reward prediction in schizophrenia. NeuroImage 29, 409-416.
36. Khandelwal, P. J., Dumanis, S. B., Herman, A. M., Rebeck, G. W., and Moussa, C. E. (2012). Wild type and P301L mutant Tau promote neuro-inflammation and alpha-Synuclein accumulation in lentiviral gene delivery models. Mol. Cell. Neurosci. 49, 44-53.
37. Kuhn, S., and Gallinat, J. (2011). Resting-state brain activity in schizophrenia and major depression: a quantitative meta-analysis. Schizophr. Bull. 39, 358-365.
38. Lee, J. S., Chun, J. W., Kang, J. I., Kang, D. I., Park, H. J., and Kim, J. J. (2012). Hippocampus and nucleus accumbens activity during neutral word recognition related to trait physical anhedonia in patients with schizophrenia: an fMRI study. Psychiatry Res. 203, 46-53.
39. Lennertz, L., Wagner, M., Frommann, I., Schulze-Rauschenbach, S., Schuhmacher, A., Kühn, K. U., et al. (2010). A coding variant of the novel serotonin receptor subunit 5-HT3E influences sustained attention in schizophrenia patients. Eur. Neuropsychopharmacol. 20, 414-420.
40. Lesser, J. M., and Hughes, S. (2006). Psychosis-related disturbances. Psychosis, agitation, and disinhibition in Alzheimer's disease: definitions and treatment options. Geriatrics 61, 14-20.
41. Levy, R., and Goldman-Rakic, P. S. (2000). Segregation of working memory functions within the dorsolateral prefrontal cortex. Exp. Brain Res. 133, 23-32.
42. Li, W., Doyon, W. M., and Dani, J. A. (2012). Quantitative unit classification of ventral tegmental area neurons in vivo. J. Neurophysiol. 107, 2808-2820.
43. Liu, L., Orozco, I. J., Planel, E., Wen, Y., Bretteville, A., Krishnamurthy, P., et al. (2008). A transgenic rat that develops Alzheimer's disease-like amyloid pathology, deficits in synaptic plasticity and cognitive impairment. Neurobiol. Dis. 31, 46-57.
44. Maher-Edwards, G., Dixon, R., Hunter, J., Gold, M., Hopton, G., Jacobs, G., et al. (2011). SB-742457 and donepezil in Alzheimer disease: a randomized, placebo-controlled study. Int. J. Geriatr. Psychiatry 26, 536-544.
45. Maher-Edwards, G., Zvartau-Hind, M., Hunter, A. J., Gold, M., Hopton, G., Jacobs, G., et al. (2010). Double-blind, controlled phase II study of a 5-HT6 receptor antagonist, SB-742457, in Alzheimer's disease. Curr. Alzheimer Res. 7, 374-385.
46. Marazziti, D., Betti, L., Giannaccini, G., Rossi, A., Masala, I., Baroni, S., et al. (2001). Distribution of [3H]GR65630 binding in human brain postmortem. Neurochem. Res. 26, 187-190.
47. Markou, A., Chiamulera, C., Geyer, M. A., Tricklebank, M., and Steckler, T. (2009). Removing obstacles in neuroscience drug discovery: the future path for animal models. Neuropsychopharmacology 34, 74-89.
48. Marner, L., Frokjaer, V. G., Kalbitzer, J., Lehel, S., Madsen, K., Baaré, W. F., et al. (2012). Loss of serotonin 2A receptors exceeds loss of serotonergic projections in early Alzheimer's disease: a combined [11C]DASB and [18F]altanserin-PET study. Neurobiol. Aging 33, 479-487.
49. Masliah, E., Terry, R. D., DeTeresa, R. M., and Hansen, L. A. (1989). Immunohistochemical quantification of the synapse-related protein synaptophysin in Alzheimer disease. Neurosci. Lett. 103, 234-239.
50. McMillan, P. J., White, S. S., Franklin, A., Greenup, J. L., Leverenz, J. B., Raskind, M. A., et al. (2011). Differential response of the central noradrenergic nervous system to the loss of locus coeruleus neurons in Parkinson's disease and Alzheimer's disease. Brain Res. 1373, 240-252.
51. Menuet, C., Borghgraef, P., Matarazzo, V., Gielis, L., Lajard, A. M., Voituron, N., et al. (2011). Raphe tauopathy alters serotonin metabolism and breathing activity in terminal Tau.P301L mice: possible implications for tauopathies and Alzheimer's disease. Respir. Physiol. Neurobiol. 178, 290-303.
52. Merrimack, (2012). Merrimack Pharmaceuticals to Present Preliminary Clinical Data for Novel Therapies Targeting Molecular Pathways in Advanced Cancer. Available at: http://investors.merrimackpharma.com/releasedetail.cfm?ReleaseID=707657
53. Mintzer, J., Rosenberg, P., Drye, L., Scherer, R., Herrmann, N., and Lanctot, K. (2012). Apathy in dementia methylphenidate trial (ADMET): preliminary report P1-003. Alzheimers Dement. 8(Suppl. 311), P108.
54. Ness, S., Rafii, M., Aisen, P., Krams, M., Silverman, W., and Manji, H. (2012). Down's syndrome and Alzheimer's disease: towards secondary prevention. Nat. Rev. Drug Discov. 11, 655-656.
55. Nicholas, T. A. IV, Bernhagen, M. A., and Boedeker, B. H. (2012). Nasotracheal intubation in a difficult airway using the Storz C-MAC Videolaryngoscope, the Boedeker Bougie endotracheal introducer, and the Boedeker curved forceps. Stud. Health Technol. Inform. 173, 310-312.
56. Okun, I., Tkachenko, S. E., Khvat, A., Mitkin, O., Kazey, V., and Ivachtchenko, A. V. (2010). From anti-allergic to anti-Alzheimer's: molecular pharmacology of Dimebon. Curr. Alzheimer Res. 7, 97-112.
57. Palmer, A. M., and DeKosky, S. T. (1993). Monoamine neurons in aging and Alzheimer's disease. J. Neural Transm. Gen. Sect. 91, 135-159.
58. Panza, F., Frisardi, V., Solfrizzi, V., Imbimbo, B. P., Logroscino, G., Santamato, A., et al. (2012). Immunotherapy for Alzheimer's disease: from anti-beta-amyloid to tau-based immunization strategies. Immunotherapy 4, 213-238.
59. PhRMA. (2012). Stepping Stones and SetBack in Alzheimer's Disease. Available at: http://www.fiercebiotech.com/press-releases/setbacks-stepping-stones-alzheimers-disease (FierceBiotech website).
60. Pirini, M., Rocchi, L., Sensi, M., and Chiari, L. (2009). A computational modelling approach to investigate different targets in deep brain stimulation for Parkinson's disease. J. Comput. Neurosci. 26, 91-107.
61. Povysheva, N. V., Zaitsev, A. V., Rotaru, D. C., Gonzalez-Burgos, G., Lewis, D. A., and Krimer, L. S. (2008). Parvalbumin-positive basket interneurons in monkey and rat prefrontal cortex. J. Neurophysiol. 100, 2348-2360.
62. Proitsi, P., Lupton, M. K., Reeves, S. J., Hamilton, G., Archer, N., Martin, B. M., et al. (2012). Association of serotonin and dopamine gene pathways with behavioral subphenotypes in dementia. Neurobiol. Aging 33, 791-803.
63. Rey, N. L., Jardanhazi-Kurutz, D., Terwel, D., Kummer, M. P., Jourdan, F., Didier, A., et al. (2012). Locus coeruleus degeneration exacerbates olfactory deficits in APP/PS1 transgenic mice. Neurobiol. Aging 33, 426.e1-426.e11.
64. Roberts, P., Seevaratnam, R., Cardoso, R., Law, C., Helyer, L., and Coburn, N. (2012a). Systematic review of pancreaticoduodenectomy for locally advanced gastric cancer. Gastric Cancer 15(Suppl. 1), S108-S115.
65. Roberts, P. D., Spiros, A., and Geerts, H. (2012b). Simulations of symptomatic treatments for Alzheimer's disease: computational analysis of pathology and mechanisms of drug action. Alzheimers Res. Ther. 4, 50.
66. Rubin, J. E., and Terman, D. (2004). High frequency stimulation of the subthalamic nucleus eliminates pathological thalamic rhythmicity in a computational model. J. Comput. Neurosci. 16, 211-235.
67. Salomone, S., Caraci, F., Leggio, G. M., Fedotova, J., and Drago, F. (2012). New pharmacological strategies for treatment of Alzheimer's disease: focus on disease modifying drugs. Br. J. Clin. Pharmacol. 73, 504-517.
68. Schneider, L. S., and Sano, M. (2009). Current Alzheimer's disease clinical trials: methods and placebo outcomes. Alzheimers Dement. 5, 388-397.
69. Sheiner, L. B. (1997). Learning versus confirming in clinical drug development. Clin. Pharmacol. Ther. 61, 275-291.
70. Sidiropoulou, K., Lu, F. M., Fowler, M. A., Xiao, R., Phillips, C., Ozkan, E. D., et al. (2009). Dopamine modulates an mGluR5-mediated depolarization underlying prefrontal persistent activity. Nat. Neurosci. 12, 190-199.
71. Slifstein, M., Kolachana, B., Simpson, E. H., Tabares, P., Cheng, B., Duvall, M., et al. (2008). COMT genotype predicts cortical-limbic D1 receptor availability measured with [11C]NNC112 and PET. Mol. Psychiatry 13, 821-827.
72. Spiros, A., Carr, R., and Geerts, H. (2010). Not all partial dopamine D(2) receptor agonists are the same in treating schizophrenia. Exploring the effects of bifeprunox and aripiprazole using a computer model of a primate striatal dopaminergic synapse. Neuropsychiatr. Dis. Treat. 6, 589-603.
73. Spiros, D., Nikolaos, R., and Ioannis, C. (2011). Minimally invasive parathyroidectomy in patients with previous endocrine surgery. JSLS 15, 499-503.
74. Steele, J. W., Lachenmayer, M. L., Ju, S., Stock, A., Liken, J., Kim, S. H., et al. (2012). Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. Mol. Psychiatry doi: 10.1038/mp.2012.106 [Epub ahead of print].
75. Sterniczuk, R., Antle, M. C., Laferla, F. M., and Dyck, R. H. (2010). Characterization of the 3xTg-AD mouse model of Alzheimer's disease: part 2. Behavioral and cognitive changes. Brain Res. 1348, 149-155.
76. Swinney, D. C., and Anthony, J. (2011). How were new medicines discovered? Nat. Rev. Drug Discov. 10, 507-519.
77. Thomsen, M. S., Hansen, H. H., Timmerman, D. B., and Mikkelsen, J. D. (2010). Cognitive improvement by activation of alpha7 nicotinic acetylcholine receptors: from animal models to human pathophysiology. Curr. Pharm. Des. 16, 323-343.
78. Traub, R. D., Wong, R. K., Miles, R., and Michelson, H. (1991). A model of a CA3 hippocampal pyramidal neuron incorporating voltage-clamp data on intrinsic conductances. J. Neurophysiol. 66, 635-650.
79. Williamson, P. C., and Allman, J. M. (2012). A framework for interpreting functional networks in schizophrenia. Front. Hum. Neurosci. 6:184. doi: 10.3389/fnhum.2012.00184
80. Wolfe, M. S. (2012). Gamma-secretase inhibitors and modulators for Alzheimer's disease. J. Neurochem. 120(Suppl. 1), 89-98.
81. Young, J. W., Powell, S. B., Risbrough, V., Marston, H. M., and Geyer, M. A. (2009). Using the MATRICS to guide development of a preclinical cognitive test battery for research in schizophrenia. Pharmacol. Ther. 122, 150-202.
82. Zaitsev, A. V., Povysheva, N. V., Gonzalez-Burgos, G., Rotaru, D., Fish, K. N., Krimer, L. S., et al. (2009). Interneuron diversity in layers 2-3 of monkey prefrontal cortex. Cereb. Cortex 19, 1597-1615.